StreetInsider.com News Articles

Form 8-K RADNOSTIX INC For: Jul 16

Tue, 21 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260721/26796310.html

Form 8-K RADNOSTIX INC For: Jul 16

Tue, 21 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260721/26796310.html

Radnostix acquires Lucerno Dynamics assets for radiopharma portfolio

Thu, 02 Jul 2026 10:43:28 -0400

Radnostix, Inc. (OTCQB: INIS) announced the closing of its acquisition of key assets from Lucerno Dynamics, LLC, including the LARA® System technology platform, the ELLEXA® Explorer software, and associated intellectual property, according to a press release dated July 2, 2026.

The LARA System was developed to identify extravasations of intravenously administered radiopharmaceuticals and improve dosimetry. The product line has since expanded to include a real-time visualization feature intended to allow clinicians to detect extravasations during theranostics administration. According to Lucerno Dynamics CEO Ron Lattanze, the system has been used in nearly 50,000 administrations across facilities in Australia, Singapore, Japan, Europe, and

Radnostix acquires Lucerno Dynamics assets for radiopharma portfolio

Thu, 02 Jul 2026 10:43:28 -0400

Radnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device Portfolio

Thu, 02 Jul 2026 10:42:00 -0400

IDAHO FALLS, Idaho, July 2, 2026 /PRNewswire/ -- Radnostix, Inc. (OTCQB: INIS) ("Radnostix" or the "Company"), a leader in radioisotope production and nuclear medicine solutions, today announced the successful closing of its acquisition of key assets from Lucerno Dynamics, LLC, including the LARA® System technology platform, ELLEXA® Explorer software and associated intellectual property.

The product line was originally developed to identify, improve dosimetry of, and reduce the frequency of extravasations of IV administered radiopharmaceuticals. Recently, the product line expanded to include a Real-Time Visualization feature. Clinicians can now stop extravasations as they

Radnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device Portfolio

Thu, 02 Jul 2026 10:42:00 -0400

Radnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device Portfolio

Thu, 02 Jul 2026 10:42:00 -0400

Radnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device Portfolio

Thu, 02 Jul 2026 10:42:00 -0400

Form 8-K RADNOSTIX INC For: Jun 25

Wed, 01 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260701/26720675.html

Form 8-K RADNOSTIX INC For: Jun 25

Wed, 01 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260701/26720675.html

Form 4 RADNOSTIX INC For: Jun 26 Filed by: GROSSO CHRISTOPHER G

Tue, 30 Jun 2026 21:16:00 -0400

si-local-file:///var/storage/secattach/20260630/26715306.html

Form 4 RADNOSTIX INC For: Jun 26 Filed by: GROSSO CHRISTOPHER G

Tue, 30 Jun 2026 21:16:00 -0400

si-local-file:///var/storage/secattach/20260630/26715306.html

Form DEFA14A RADNOSTIX INC

Thu, 04 Jun 2026 13:08:00 -0400

si-local-file:///var/storage/secattach/20260604/26604644.html

Form DEFA14A RADNOSTIX INC

Thu, 04 Jun 2026 13:08:00 -0400

si-local-file:///var/storage/secattach/20260604/26604644.html

Form DEF 14A RADNOSTIX INC For: Jul 16

Thu, 04 Jun 2026 12:39:00 -0400

si-local-file:///var/storage/secattach/20260604/26604533.html

Form DEF 14A RADNOSTIX INC For: Jul 16

Thu, 04 Jun 2026 12:39:00 -0400

si-local-file:///var/storage/secattach/20260604/26604533.html

Radnostix, Inc. Reports FY2026 Q1 Results - Revenue Declines 27% Primarily Due to Voluntary Product Recalls, Isotope Supply Disruptions, and Planned Operational Shutdown

Thu, 21 May 2026 11:05:00 -0400

IDAHO FALLS, Idaho, May 21, 2026 /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ("Radnostix" or the "Company"), a manufacturer of radioisotope-focused products for medical, industrial, and research applications, today announced its financial results for the first quarter ended March 31, 2026 and the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission.

First Quarter 2026 Financial and Operational Summary

Total revenue decreased 27% to $2.38 million from $3.24 million in the first quarter of 2025, driven by recall impacts,

Radnostix, Inc. Reports FY2026 Q1 Results - Revenue Declines 27% Primarily Due to Voluntary Product Recalls, Isotope Supply Disruptions, and Planned Operational Shutdown

Thu, 21 May 2026 11:05:00 -0400

First Quarter 2026 Financial and Operational Summary

Total revenue decreased 27% to $2.38 million from $3.24 million in the first quarter of 2025, driven by recall impacts,

Radnostix, Inc. Reports FY2026 Q1 Results - Revenue Declines 27% Primarily Due to Voluntary Product Recalls, Isotope Supply Disruptions, and Planned Operational Shutdown

Thu, 21 May 2026 11:05:00 -0400

First Quarter 2026 Financial and Operational Summary

Total revenue decreased 27% to $2.38 million from $3.24 million in the first quarter of 2025, driven by recall impacts,

Radnostix, Inc. Reports FY2026 Q1 Results - Revenue Declines 27% Primarily Due to Voluntary Product Recalls, Isotope Supply Disruptions, and Planned Operational Shutdown

Thu, 21 May 2026 11:05:00 -0400

First Quarter 2026 Financial and Operational Summary

Total revenue decreased 27% to $2.38 million from $3.24 million in the first quarter of 2025, driven by recall impacts,

Form 8-K RADNOSTIX INC For: May 14

Wed, 20 May 2026 15:37:00 -0400

si-local-file:///var/storage/secattach/20260520/26527933.html

Form 8-K RADNOSTIX INC For: May 14

Wed, 20 May 2026 15:37:00 -0400

si-local-file:///var/storage/secattach/20260520/26527933.html

Form 10-Q RADNOSTIX INC For: Mar 31

Wed, 20 May 2026 14:36:00 -0400

si-local-file:///var/storage/secattach/20260520/26527616.html

Form 10-Q RADNOSTIX INC For: Mar 31

Wed, 20 May 2026 14:36:00 -0400

si-local-file:///var/storage/secattach/20260520/26527616.html

Form NT 10-Q RADNOSTIX INC For: Mar 31

Fri, 15 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260515/26506513.html